Cuu Long Pharmaceutical JSC

Cuu Long Pharmaceutical JSC maintains a relatively conservative capital structure, with a debt-to-equity ratio of 0.48, indicating a moderate reliance on debt financing. However, the company's liquidity position is weak, as evidenced by a negative operating cash flow of -10,957,907,670 VND and a free cash flow of -43,963,275,140 VND. The absence of cash and equivalents further exacerbates this liquidity challenge.

Profitability metrics for the company are modest. The return on equity (ROE) is 1.51%, and the return on assets (ROA) is 0.92%, both of which are below the industry median for pharmaceutical firms. This suggests that the company is underperforming in terms of generating returns relative to its equity and asset base.

The company's revenue is concentrated in a single geographic market, Vietnam, with no disclosed international operations. This lack of geographic diversification increases exposure to local economic and regulatory risks. Additionally, the company does not report segment-specific revenue, making it difficult to assess the performance of different product lines or therapeutic areas.

Looking ahead, the company's growth trajectory is uncertain. While the current fiscal year (FY) shows a revenue of 277,940,285,210 VND, there is no disclosed revenue growth rate or specific guidance for the next FY. The absence of capital expenditure (capex) growth and the negative free cash flow suggest that the company may be facing operational or strategic challenges.

The company's risk profile is characterized by medium liquidity risk and low dilution risk. The negative net cash position after subtracting total debt is a key flag, indicating potential difficulties in meeting short-term obligations. However, the low dilution risk suggests that the company is not currently issuing new shares at a rate that would significantly dilute existing shareholders.

Recent events and filings do not provide specific details on strategic initiatives or major corporate actions. The company's 10-K filings and other disclosures do not highlight any significant recent developments, such as new product launches, partnerships, or regulatory approvals.

Net margin of 8.0% is double the cohort median of 3.9%, demonstrating strong profitability relative to peers.

Free cash flow improved by 81.9% year-over-year, signaling a positive trend in cash generation efficiency.

Revenue grew at a 17.1% CAGR over four years, showing consistent top-line expansion despite recent volatility.

Dilution risk is assessed as low, providing stability for existing shareholders regarding equity value erosion.

Cash conversion ratio of -0.49 places the company in the bottom quartile of its pharmaceutical cohort.

High credit risk flags potential solvency concerns, exacerbated by long-term debt exceeding 778 billion VND.